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Background: The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete
response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
We investigated the efficacy of T or L with neoadjuvant chemotherapy and specific efficacy biomarkers.
Methods: Patients with stages I–III (including inflammatory) HER2-positive breast cancer were randomised to receive epirubicin (E)
plus cyclophosphamide (C)  4 cycles followed by docetaxel (D) plus either T (EC-DT) or L (EC-DL). End points included pCR
(primary), clinical response, toxicity, and pCR-predictive biomarkers.
Results: We randomised 102 patients to EC-DT (50) and EC-DL (52). Median age was 48, 56% were premenopausal and 58% had
oestrogen receptor (ER)-positive tumours. Pathological complete response in breast was 52.1% (95% CI:38.0–66.2%) for EC-DT and
25.5% (95% CI:13.5–37.5%) for EC-DL (P¼ 0.0065). Pathological complete response in breast and axilla was 47.9% for EC-DT and
23.5% for EC-DL (P¼ 0.011). Grade 3–4 toxicity did not differ across treatments, except for diarrhoea (2% in EC-DT vs 13.5% in EC-DL,
P¼ 0.030). Multivariate analyses showed that treatment (P¼ 0.036) and ER (P¼ 0.014) were the only predictors of pCR in both groups.
Conclusion: EC-DT exhibited higher efficacy and lower toxicity than EC-DL. Of the different biomarkers studied, only the absence
of ER expression was associated with increased pCR.
Breast cancer is a heterogeneous disease including distinct biological
subtypes with distinct natural histories. Breast cancer exhibits a
wide spectrum of clinical presentations as well as diverse pathologic
and molecular features, each with its distinctive prognostic and
therapeutic implications (Bertucci and Birnbaum, 2008).
Neoadjuvant chemotherapy (NAC) has been the preferred
treatment for locally advanced and inflammatory breast cancer
patients. A multimodality approach, including NAC, surgery, and
radiation, is the most effective treatment option as shown by better
overall survival outcomes (Kaufmann et al, 2007). NAC has shown
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high clinical and pathological response rates and it increases the
chance for breast conservation; thus, it is currently the preferred
treatment for large resectable tumours (Fisher et al, 1997).
Irrespectively of the disease stage at diagnosis, patients achieving
pathological complete response (pCR) exhibit better survival
outcomes (Kuerer et al, 1999; Rouzier et al, 2002; Hennessy et al,
2005; Guarneri et al, 2006; Rastogi et al, 2008). With regards to
tumour biology, the impact of pCR in patient prognosis has been
recently defined according to the intrinsic subtypes in a retro-
spective analysis of several German neoadjuvant studies. According
to this meta-analysis, pCR is a suitable surrogate end point for
patients with human epidermal growth factor receptor 2 (HER2)-
positive (nonluminal), triple negative, and luminal B/HER2-
negative tumours but not, however, for luminal B/HER2-positive
and luminal A tumours (von Minckwitz et al, 2012). Thus, the
identification and evaluation of new drug regimens that improve
pCR rates in operable tumours are becoming the main objectives of
NAC protocols, with the ultimate goal of achieving better survival
outcomes. Further, the neoadjuvant setting permits an in vivo
evaluation of treatment efficacy and allows the identification of
subgroups of patients with different prognoses.
The HER2 is overexpressed in 15–20% of breast cancer, and it is
associated with a highly aggressive tumour behaviour and poor
outcomes. The availability of the anti-HER2 monoclonal antibody
(mAb) trastuzumab has significantly improved the prognoses of
patients with HER2-positive breast cancer both in early and
advanced disease (Slamon et al, 2001; Marty et al, 2005; Piccart-
Gebhart et al, 2005; Romond et al, 2005; Joensuu et al, 2006;
Slamon et al, 2011). Lapatinib is a dual tyrosine kinase inhibitor of
HER1 and HER2, currently approved for the treatment of patients
with HER2-positive advanced breast cancer who fail to respond to
trastuzumab therapy (Spector et al, 2005; Geyer et al, 2006;
Konecny et al, 2006; Cameron et al, 2008; Di Leo et al, 2008;
Gomez et al, 2008). Recent studies show that, in the preoperative
setting, the combination of trastuzumab with sequential che-
motherapy with taxanes and anthracyclines results in a high pCR
rate (Buzdar et al, 2007; Gianni et al, 2010; Untch et al, 2010).
On the basis of the existing evidence, we designed a phase II
randomised study of standard chemotherapy with epirubicine (E),
cyclophosphamide (C), and docetaxel (D) in combination with
either trastuzumab or lapatinib. The main goal of the study was to
evaluate the efficacy and safety of these two neoadjuvant
treatments for HER2-positive breast cancer patients. Additionally,
as an exploratory end point we examined the putative predictive
role of various biomarkers on pathological response. These
biomarkers, present in pretreatment tumour biopsies, were selected
based on reported in vitro and clinical trial data as well as on their
potential to mediate growth factor-induced changes in tumour
growth, including hormonal receptors, proliferation and activation
of ERK and PI3K/AKT signalling pathways (Okano et al, 2000; Xia
et al, 2002; Song et al, 2005; Spector et al, 2005; Dave et al, 2011;
Luporsi et al, 2012).
PATIENTS AND METHODS
Eligibility criteria. Female subjects with histologically proven
stages I, II, III or inflammatory breast cancer (by breast core
biopsy) and HER2-positive status, by local results, were included in
this study. HER2 amplification was confirmed by Pathvysion FISH
probes in a central laboratory, following the ASCO/CAP guidelines
(Wolff et al, 2007). Patients were eligible only if they were at least
18 years of age; had a Karnofsky performance status (PS)X80; had
adequate bone marrow, liver, renal, and cardiac functions; and
were treatment-naive. For women of childbearing age, a negative
pregnancy test and use of adequate contraception were also
required. Patients were excluded if they had the following: bilateral
invasive or metastatic breast cancer, a pre-existing neurotoxicity
grade X2 (based on the National Cancer Institute-Common
Terminology Criteria for adverse events version 3.0 (NCI-CTCAE
v3.0) score system (Cancer Therapy Evaluation Program (CTEP),
2006)), a previous history of cancer other than cervical or non-
melanoma skin cancer adequately treated, or other malignant
tumours treated more than 10 years before the study entry; or any
other severe or uncontrolled systemic disease. All patients provided
written informed consent before study entry.
Study design and treatment plan. This was a multicentre, open-
label, randomised phase II trial. All eligible patients were randomly
assigned in a 1 : 1 ratio to NAC treatment either with EC 4
cycles-docetaxelþ trastuzumab 4 (standard arm, EC-DT) or
EC 4-docetaxelþ lapatinib 4 (experimental arm, EC-DL).
Randomisation was centralised at the headquarters of the Spanish
Breast Cancer Research Group (GEICAM for its Spanish
acronym). Patients were stratified according to tumour size
(T1–T2 vs T3 vs T4) and oestrogen receptor (ER) status (ER-positive
vs ER-negative).
Specifically, NAC consisted of epirubicin 90mgm 2 plus
cyclophosphamide 600mgm 2 both administered intravenously
(IV) on day 1 every 21 days for four cycles followed by docetaxel
100mgm 2 also administered IV on day 1 every 3 weeks for four
cycles. The anti-HER2 therapy was added to docetaxel as follows:
patients in the standard arm received T 6mgkg 1 (after a loading
dose of 8mgkg 1) administered IV on day 1 every 21 days (EC-DT),
whereas patients in the experimental arm were administered a
daily dose of lapatinib 1250mg orally (EC-DL) (Figure 1). Upon
completion of the NAC treatment, patients underwent mastectomy
or conservative surgery plus axillary lymph node dissection (unless
previous negative sentinel lymph node biopsy). Postoperative
treatment was left at the investigator’s criteria.
This trial was approved by the local Ethical Review Boards of
the recruitment sites and the Spanish Ministry of Health. It is
registered in ClinicalTrials.Gov with the number NCT00841828.
The trial was conducted in compliance with Good Clinical
Practices and the tenets of the Declaration of Helsinki. Written
informed consent was obtained from all patients before study
entry.
Assessments and end points. The primary end point of this study
was to determine the pCR rate in the breast upon NAC treatment
completion. Secondary end points included toxicity and clinical
response rates (by a radiological method). Additionally, through
analyses of the tumour samples prespecified in the study protocol,
we explored potentially predictive associations between tumour
biomarkers and pCR.
Before study entry, all patients underwent a breast and axillary
disease assessment by ultrasound, mammography, or magnetic
resonance imaging (MRI). In addition, patients had an ECOG PS
evaluation, a core biopsy, HER2-positive assessment, a complete
blood cell count, serum chemistry, an electrocardiogram, and a left
ventricular ejection fraction (LVEF) measurement.
pCR was assessed at surgery based on the Miller and Payne
criteria (Ogston et al, 2003). Clinical response defined as complete
response (CR)þ partial response (PR) was evaluated according to
the Response Evaluation Criteria in Solid Tumours (RECIST)
criteria (Therasse et al, 2000) after the fourth EC cycle and before
surgery (upon NAC completion) using ultrasound, mammogra-
phy, or MRI. Specific response end points evaluated include the
following: pCR rate in the breast defined as the absence of any
residual invasive tumour in the breast, residual DCIS permitted
(grade 5 according to Miller and Payne classification); breast and
axilla pCR defined as the absence of any residual invasive tumour
in the breast and axilla at diagnosis in node-negative patients
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(grade 5-A) or in node-positive patients (grade 5-D). Adverse
events were graded according to the NCI-CTCAE version 3.0
(Cancer Therapy Evaluation Program (CTEP), 2006). The worst
grade for each patient was reported. LVEF was evaluated after the
fourth EC cycle and, again, at the end of NAC and before surgery.
Putative predictive biomarker assessment. Biomarker analysis by
immunohistochemistry was carried out at a central laboratory.
Immunostaining was performed using 3-mm formalin-fixed,
paraffin-embedded tissue sections in Dako Autostainer platforms.
Briefly, after deparaffinisation, heat antigen retrieval was per-
formed in a pH9 EDTA-based buffered solution. Endogenous
peroxidase was blocked by immersing the sections in 0.03%
hydrogen peroxide for 5min. Sections were incubated with
primary mAbs for ER (clone EP1, Dako, Glostrup, DK, USA),
PR (PgR636, Dako), Ki67 (MIB1, Dako), PTEN (6H2.1, Dako),
rabbit mAb total ERK1/2 (137F5, Cell Signalling, Danvers, MA,
USA), phosphorylated (p) ERK1/2 at Thr202/Tyr204 (D13.14.4E,
Cell Signalling), AKT (11E7, Cell Signalling), and p-AKT at Ser473
(D9E, Cell Signalling). Detection was performed by EnVision
FLEX system (Dako). The same sections incubated with non-
immunised serum were used as negative controls, whereas sections
of a human tumour with a known marker expression were assayed
as positive controls.
The expression of the studied markers was assessed by a
pathologist blinded to clinical parameters. ER and PR status were
classified as positive according to the ASCO/CAP guidelines
(Hammond et al, 2010) based on a threshold of 1%. HER2
amplification was confirmed by Pathvysion FISH probes (Vysis
Abbott Molecular, Abbott Park, IL, USA) in a central laboratory
following the ASCO/CAP guidelines (Wolff et al, 2007). The cut
point considered for Ki67 expression was 14% based on the
optimal threshold determined by Cheang et al (2009) to distinguish
luminal B from luminal A tumours. PTEN was scored semi-
quantitatively using the immunoreactive score (IRS). IRS was
defined as: IRS¼ Staining Intensity (SI) Positivity Percentage
(PP); where SI was categorised as 0¼ negative, 1¼weak,
2¼moderate, and 3¼ strong; and PP as 0¼o1%; 1¼ 1–10%;
2¼ 11–50%; 3¼ 51–80%; and 4¼480% positive cells. High PTEN
was defined as an IRS X6 (Nagata et al, 2004). For ERK1/2 and
AKT, a semiquantitative HistoScore (Hscore) was calculated
estimating the percentage of tumour cells positively stained at the
nucleus with low, medium, or high staining intensity. A final score
was determined applying a weighting factor to each estimate,
following a formula: H-score¼ (low %) 1þ (medium %) 2
þ (high %) 3. The results ranged from 0 to 300, and the median
values were considered as high expression cutoffs. The expression
of phosphorylated forms of ERK1/2 and AKT was corrected with
the total protein expression.
Statistical considerations. The sample size of the experimental
arm was calculated using the 2-stage Simon method and with pCR
as the primary study end point. Sample size was based on the null
hypothesis of a pCR of 40% and an alternative hypothesis of a pCR
of 60%. Assuming an alpha error of 0.05 and a test power of 80%,
92 evaluable patients were required to be recruited and retained in
the study. Sixteen patients per arm were to be included in the first
stage, for at least eight pCR per arm to be seen, and 30 additional
patients per arm were to be included in the second stage for a total
of 46 evaluable patients in each arm. Assuming a 10% drop-out
rate, 102 patients were recruited.
The efficacy variables (pCR and clinical response) were analysed
in the evaluable population (defined as the randomised and treated
HER2-positive patients). The number and proportion of patients
experiencing response in each treatment arm, and the correspond-
ing two-sided 95% CIs, were calculated for the best overall
response. For hypothesis generation, we used w2 to compare the
rate of response and adverse events between treatment arms.
Univariate analyses and multivariate logistic regression analyses
were used to study the association of biomarkers with clinical end
points. Expression scores were analysed as dichotomous variables
(that is, high/low expression groups) or entered as continuous
variables. In the multivariate analysis we selected the variables
associated with pCR using the stepwise method. All analyses were
performed using the Statistical Analysis System (SAS) Enterprise
Guide 4.3 software (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient characteristics. Between February 2009 and October
2010, 102 patients from 16 participating centres were included
and randomised (50 to EC-DT and 52 to EC-DL). HER2 status was
retrospectively evaluated in a central laboratory by IHC and 3þ
results were considered HER2-positive, whereas 2þ results were
considered equivocal and further tested using FISH.
Three patients were FISH-negative in the central analysis (two
patients in the EC-DT and one in the EC-DL arm), which rendered
them non-evaluable for efficacy. Thus, 99 patients were evaluable
for efficacy (48 and 51 in the EC-DT and EC-DL, respectively),
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Figure 1. Trial design.
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however, all 102 patients were evaluable for safety (on an
intention-to-treat analysis). Patients’ and tumour characteristics
are summarised in Table 1. No statistically significant differences
were observed in any clinicopathological characteristics between
treatment arms. The median age was 48 years (range: 30–79 years),
56% of the patients were premenopausal, 46% of tumours were
grade III, 59% T2, and 69% of patients were node-positive.
Regarding hormone receptor status (local assessment), 58% were
ERþ , 44% PRþ , 42% were ERþ PRþ , and 16% ERþ PR . ER
and PR expressions were also confirmed by a central laboratory,
showing an agreement of 88.6% and 84.8%, respectively.
Figure 2 shows the CONSORT study flow chart (Schulz et al,
2010). Twelve patients, 2 and 10 in the EC-DT and EC-DL arms,
respectively, discontinued treatment early (P¼ 0.0143). The main
reason for discontinuation was as follows: toxicity in seven patients
(one in EC-DT and six in EC-DL, P¼ 0.0551). Out of the six
patients who withdrew from the lapatinib arm due to toxicity, four
cases were related to lapatinib as follows: one grade 3 supraven-
tricular arrhythmia; one grade 4 mucositis–estomatitis plus grade 4
skin rash; one grade 3 diarrhoea; and one grade 3 diarrhoea plus
grade 3 skin rash. Other reasons for discontinuation included
HER2 negativity in two patients (one in each arm), and three
patient withdrawals. Thus, 90 patients, 48 in the EC-DT arm (one
of them HER2-negative) and 42 in the EC-DL arm, completed the
treatment as planned.
Dose administration. The EC regimen has been described in
detail elsewhere (Alba et al, 2012). A total of 195 cycles of DT and
181 cycles of DL were administered. In the standard arm, 8.7% of
the DT cycles were delayed; 6.2% of docetaxel doses were omitted
or reduced, and all trastuzumab doses were administered as
planned. In the experimental arm, 8.8% of the DL cycles were
delayed; 7.7% of docetaxel doses were omitted or reduced, and the
lapatinib doses were omitted or reduced in 18.2% of the cycles.
The main reasons for dose modification with the DT
combination were neutropenia (4.1%), fatigue (2.5%), infection
(2.1%), and transaminase elevation (2.1%), whereas in the DL
combination were diarrhoea (8.8%), rash (7.7%), and neutropenia
(2.2%). The median relative dose intensity for docetaxel was 99.8%
in both treatment arms, 99.8% for trastuzumab, and 96.4% for
lapatinib.
Toxicity. Table 2 summarises all grade 3–4 adverse events in the
study. The most frequent grade 3–4 toxicity was neutropenia,
observed in 23 cases (22%), and two patients (2%) suffered febrile
neutropenia. Grade 3–4 toxicity rates were similar across arms
except for diarrhoea, which was more frequent among the EC-DL
than the EC-DT arm patients (13.5% vs 2%; P¼ 0.03). More
patients in the EC-DL arm discontinued treatment due to toxicity
than in the EC-DT arm (6 vs 1, respectively; P¼ 0.055).
No cases of symptomatic congestive heart failure (CHF) (grade
3–4 LVEF decline) were observed. The median LVEF was 63%
(range: 52–88%) at baseline and 63% (range: 40–85%) at the end of
treatment. Only three patients had asymptomatic grade 2 LVEF
decline during treatment (two patients on EC-DT arm and one
patient on EC-DL arm) and none of them discontinued treatment
for this reason.
Efficacy. Table 3 shows treatment efficacy data. The attained pCR
rate in the breast (grade 5 according to Miller and Payne
classification) was significantly higher in the EC-DT group
(52.1% of patients, 95% CI: 38–66.2%) compared with the
EC-DL-treated patients (25.5% of cases, 95% CI: 13.5–37.5%)
(P¼ 0.0065). Moreover, breast and axilla pCR in node-negative
patients (grade 5-A) and in node-positive patients (grade 5-D) was
also superior in the EC-DT regimen (47.9%, 95% CI: 33.8–62.0%)
than in the EC-DL one (23.5, 95% CI: 11.9–35.1%, P¼ 0.0112).
After the four EC cycles, the overall clinical response rate (ORR)
was similar in both treatment arms (47.9% for EC-DT and 45.1%
from EC-DL, P¼ 0.7787). However, the differences in the ORR of
the two groups before surgery, although numerically different, were
also not significantly different statistically speaking (77% in the
EC-DT arm and 63% in the EC-DL arm; P¼ 0.1208).
All patients evaluable for efficacy underwent surgery.
Breast conservation was achieved in 58 patients (58.6%)
(28 patients in the EC-DT arm and 30 patients in the EC-DL
arm). At the univariate level, pCR was associated with ER
status (local results) regardless of treatment (34.3% in ERþ
tumours vs 66.5% in ER tumours; P¼ 0.0008). Univariate
Table 1. Patient characteristics by treatment regimen
EC-DT EC-DL
Characteristics n ¼50 n ¼52
Age, median (range) 48.5 (32–74) 48 (30–79)
ECOG PS, n (%)
0 46 (92.0) 47 (90.4)
1 4 (8.0) 5 (9.6)
Menopausal status, n (%)
Premenopausal 29 (58.0) 28 (53.9)
Postmenopausal 21 (42.0) 24 (46.1)
Estrogen receptor
Positive 30 (60.0) 29 (55.8)
Negative 20 (40.0) 23 (44.2)
Progesterone receptor
Positive 21 (42.0) 24 (46.2)
Negative 29 (58.0) 28 (53.8)
Estrogen receptor/progesterone receptor
ERþ /PRþ 21 (42.0) 22 (42.3)
ERþ /PR- 9 (18.0) 7 (13.5)
Histologic type, n (%)
Ductal 48 (96.0) 48 (92.3)
Lobular 0 (0.0) 1 (1.9)
Other 2 (4.0) 3 (5.8)
Tumor grade, n (%)
1 5 (10.0) 2 (3.8)
2 15 (30.0) 17 (32.7)
3 22 (44.0) 25 (48.1)
Unknown 8 (16.0) 8 (15.4)
Tumour size, n (%)
T1 6 (12.0) 8 (15.4)
T2 31 (62.0) 29 (55.8)
T3 4 (8.0) 8 (15.4)
T4 9 (18.0) 7 (13.4)
Median tumour size, cm (range) 3.3 (1.0–10.0) 3.5 (1.0–15.8)
Nodal status, n (%)
N0 13 (26.0) 19 (36.5)
N1 35 (70.0) 32 (61.6)
N2 2 (4.0) 1 (1.9)
Abbreviations: EC-DL¼ epirubicin plus cyclophosphamide x 4 cycles followed by docetaxel
plus lapatinib; EC-DT¼ epirubicin plus cyclophosphamide x 4 cycles followed by docetaxel
plus trastuzumab; ECOG¼Eastern Cooperative Oncology Group.
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analyses per arm, however, suggested that the ER status effect on
pCR is found in the trastuzumab-treated patients (OR¼ 7.5 (95%
CI: 2.04–27.6; P¼ 0.0024) for ER vs ERþ ) but not in the
lapatinib-treated group (OR¼ 3.6 (95% CI: 0.9–14.0; P¼ 0.0680)
for ER vs ERþ ).
Tumour markers and clinicopathological variables predictive of
anti-HER2 efficacy. We performed biomarker central analyses in
79 patients (77.5%) with available pretreatment tumour samples.
Sixteen cases (20.3%) showed the loss of PTEN expression, and 19
patients (24.1%) presented low expression of Ki67. ER and PR
expressions were detected in the 64.6% and 43.0% of cases,
respectively. Proportions of cases with ERK and AKT over-
expression were 69.6% and 88.6%, respectively.
The results of the univariate and multivariate analyses are
summarised in Tables 4 and 5. At the univariate level, only
EC-DT
n = 50
EC-DL
n = 52
Randomised (n = 102)
Early treatment
discontinuation n = 2 
Toxicity: 1
HER2-negative: 1*
Other: 0
Received complete
treatment n = 48
HER2-negative: 1*
Early treatment
discontinuation  n = 10
Toxicity: 6
HER2-negative: 1*
Other: 3
Received complete
treatment n = 42
* Not evaluable for efficacy
Figure 2. Consort study flowchart.
Table 2. Grade 3–4 Adverse events based on the National Cancer
Institute-Common Terminology Criteria for Adverse Events
(NCI-CTCAE) version 3.0
EC-DT EC-DL
Adverse eventa, n (%) n ¼50 n ¼52 P-value
Leukocytes, (total WBC) 5 (10.0) 10 (19.2) 0.0961
Lymphopenia 1 (2.0) 6 (11.5) 0.0551
Neutropeniab 10 (20.0) 13 (25.0) 0.5458
Rash/desquamation 0 (0.0) 4 (7.7) 0.0637
Diarrhea 1 (2.0) 7 (13.5) 0.0305
Nausea and vomiting 0 (0.0) 3 (5.8) 0.1287
ALT, SGPT 3 (6.0) 0 (0.0) 0.1142
Infection 0 (0.0) 2 (3.8) 0.2574
Fatigue 6 (12.0) 2 (3.8) 0.0961
Anyc 21 (42.0) 28 (53.8) 0.2313
Abbreviations: EC-DL¼ epirubicin plus cyclophosphamide x 4 cycles followed by docetaxel
plus lapatinib; EC-DT¼ epirubicin plus cyclophosphamide x 4 cycles followed by docetaxel
plus trastuzumab.
aGrade 3–4 adverse events X3% in total.
bOne patient per treatment arm experienced febrile neutropenia.
cPatients with any grade 3–4 adverse event.
Table 3. Treatment efficacy—pathological response by treatment
regimen
EC-DT EC-DL
Pathological responsea n (%) n ¼48 n ¼51
Grade 1 2 (4.2) 2 (3.9)
Grade 2 6 (12.5) 6 (11.8)
Grade 3 9 (18.7) 13 (25.5)
Grade 4 6 (12.5) 11 (21.5)
Grade 5b 25 (52.1) 13 (25.5)
Unknown 0 (0) 6c (11.8)
pCR breast 25 (52.1) 13 (25.5)
(95% CI) (38.0–66.2) (13.5–37.5)
P-value¼ 0.0065
pCR breast and axilla (Grade 5-A & 5-D)d 23 (47.9) 12 (23.5)
(95% CI) (33.8–62.0) (11.9–35.1)
P-value¼ 0.0112
Abbreviations: EC-DL¼epirubicin plus cyclophosphamide x 4 cycles followed by docetaxel
plus lapatinib; EC-DT¼ epirubicin plus cyclophosphamide x 4 cycles followed by docetaxel
plus trastuzumab; pCR¼pathological complete response.
aGrade 1-Grade 5: Miller and Payne classification of pathological response.
bAbsence of any residual invasive tumour in the breast, residual DCIS permitted.
cAll six patients were withdrawn from the study and treated with a different therapy. Four
cases were related to lapatinib as follows: 1 grade 3 supraventricular arrhythmia; 1 grade 4
mucositis-estomatitis plus grade 4 skin rash; 1 grade 3 diarrhea; and 1 grade 3 diarrhea plus
grade 3 skin rash.
dThe absence of any residual invasive tumour in the breast and axilla at diagnosis in
node-negative patients (grade 5-A) or in node-positive patients (grade 5-D).
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treatment (P¼ 0.038), ER (P¼ 0.014), and PR (P¼ 0.019)
were statistically associated with pCR in breast and axilla
(grades 5-D and 5-A according to Miller and Payne classifica-
tion; Table 4). AKT and ERK activation pathway markers were
not associated with response (P¼ 0.5799 and P¼ 0.2873,
respectively). The proportion of activated factors to total protein
expression was not correlated with response (P¼ 0.8477 and
P¼ 0.2873, respectively). Low Ki67 expression was not statistically
associated with pCR in breast and axilla (OR¼ 1.02; 95% CI:
1.00–1.04; P¼ 0.069). Only high PTEN expression approached a
significant association with a poor pCR (OR¼ 2.90; 95% CI:
0.95–8.97; P¼ 0.063).
Multivariate analyses showed that only treatment (OR¼ 2.95;
95% CI: 1.07–8.15; P¼ 0.0366) and the absence of ER expression
(OR¼ 3.56; 95% CI: 1.29–9.80; P¼ 0.014) were predictive of pCR
in breast and axilla (Table 5).
DISCUSSION
In this phase II trial we evaluated the efficacy and toxicity of
trastuzumab and lapatinib when added to standard NAC (that is,
epirubicin, cyclophosphamide, and docetaxel) for patients with
HER2-positive early stage or inflammatory breast cancer. Our
results showed that the EC-DT regimen was more efficacious and
less toxic than the EC-DL schedule. Specifically, we observed
statistically significant higher pCR rates in breast and axilla in
patients receiving the EC-DT treatment than in those treated with
the EC-DL therapy (P¼ 0.0112). It is important to point out that
pCR is increasingly accepted as a surrogate marker of disease
response to therapy and it has been associated with a favourable
long-term prognosis in patients with HER2þ tumours treated
with NAC and trastuzumab, especially in the HER2þ /ER
subgroup (Untch et al, 2010; Cortazar et al, 2012; von Minckwitz
et al, 2012). With regards to toxicity, our data showed that,
although reports of grade 3–4 neutropenia, leucopenia, and
lymphopenia were similar between treatment arms, diarrhoea
was significantly more frequent among the EC-DL patients and, in
fact, more patients in this regimen discontinued treatment due to
toxicity. It is worth noting that the cardiotoxicity observed in this
trial—asymptomatic cardiotoxicity ino4% of patients—was lower
both in severity and frequency than the levels found by Buzdar et al
(2005) who reported that one out of 45 patients developed CHF,
which they considered an exceptionally low rate.
These findings are consistent with a previous study evaluating
the efficacy of trastuzumab and lapatinib in combination with EC-
D chemotherapy in the neoadjuvant treatment of breast cancer
(Untch et al, 2012). In contrast to our study, in this 2012 clinical
trial, trastuzumab and lapatinib were added in both treatment arms
from the first cycle of therapy. The pCR rates in patients treated
with trastuzumab were superior to that of patients treated with
lapaninib (30.3% vs 22.7%, P¼ 0.04). However, not all evidence
supports this finding. For instance, the NeoALTTO (Baselga et al,
2012) and the NSBAP B41 (Robidoux et al, 2012) trials, also in the
neoadjuvant setting, randomised breast cancer patients to receive
weekly paclitaxel in combination with either trastuzumab,
lapatinib, or the double blockade with trastuzumab and lapatinib
(as the only therapy in the NeoALTTO trial and following standard
doxorubicin and cyclophosphamide therapy in the NSBAP B41
trial). These studies found no difference in pCR rates between the
trastuzumab and the lapatinib arms, although there was a
statistically significant benefit of the double blockade when
compared with the trastuzumab-alone regimen.
To date, there are no clinically validated markers of resistance to
HER2-targeted therapies. However, several mechanisms have been
proposed such as intrinsic HER2 alterations, activation of
compensatory signal transduction pathways, alterations in apop-
tosis and cell cycle control, or host factors that affect immuno-
modulatory function (Rexer and Arteaga, 2012).
In our trial, the hormonal status of patients was associated with
the likelihood of CR, suggesting that oestrogen receptor may have a
predictive role regarding a patient’s response to a specific
neoadjuvant anti-HER2 therapy. A crosstalk between the ER and
HER2 pathways has been established clinically and in vitro as
having a role in both intrinsic and acquired resistance to HER2-
directed agents (Puglisi et al, 2012) as in sustained HER2
inhibition, ER acts as a survival pathway in ER-positive/HER2-
positive cells. These data suggest the possibility that a subset of
HER2-positive, ER-positive breast cancers are driven primarily by
ER and biologically behave more like HER2-negative, ER-positive
breast cancers (Nahta and O’Regan, 2012). Efforts to identify this
subset of HER2-positive breast cancers might have a relevant role
in predicting the clinical benefit of specific therapies. These efforts
may also facilitate the design of new therapeutic approaches to
improve treatment outcomes for patients with ER-positive, HER2-
positive breast cancer.
Hyperactivation of PI3K signalling downstream of HER2, either
through loss-of-function PTEN mutations or dominant activating
mutations in the catalytic subunit of PI3K (PIK3CAa), seems to
decrease T activity in breast cancer. Thus, it has been proposed as
resistance mechanism to the anti-HER2 therapy (Dave et al, 2011).
Table 4. Factors associated with pathological complete response in
breast and axilla—Univariate analyses
P-valuea OR (95% CI)
Treatmentb (EC-DL as ref.) 0.0381 2.783 (1.058–7.323)
ER-negative 0.0144 3.373 (1.274–8.931)
PR-negative 0.0191 3.375 (1.221–9.330)
Ki67 expression 0.0690 1.019 (0.999–1.039)
Loss of PTEN expression 0.0630 2.909 (0.944–8.967)
ERK expression 0.5638 0.996 (0.984–1.009)
p-ERK expression 0.2873 1.004 (0.997–1.011)
Ratio p-ERK/ERK 0.2190 2.790 (0.543–14.331)
AKT expression 0.1602 0.993 (0.982–1.003)
p-AKT expression 0.5799 0.998 (0.993–1.004)
Ratio p-AKT/AKT 0.8477 0.869 (0.207–3.650)
Abbreviations: CI¼ confidence intervals; ER¼ estrogen receptors; OR¼Odds ratio;
PR¼progesterone receptors.
aP-values in bold are significant and P-values in italics approach significance.
bTreatment is EC-DT, epirubicin plus cyclophosphamide x 4 cycles followed by docetaxel
plus trastuzumab, and the treatment in the reference category is EC-DL, epirubicin plus
cyclophosphamide x 4 cycles followed by docetaxel plus lapatinib.
Table 5. Factors associated with pathological complete response in
breast and axilla—multivariate analyses
P-value ORa 95% CI
Treatment EC-DH vs EC-DL 0.0366 2.953 1.070–8.154
ER central-negative vs positive 0.0141 3.557 1.292–9.795
Abbreviations: CI¼ confidence interval; EC-DL¼epirubicin plus cyclophosphamide 4
cycles followed by docetaxel plus lapatinib; EC-DT¼epirubicin plus cyclophosphamide 4
cycles followed by docetaxel plus trastuzumab; ER¼oestrogen receptor; OR¼Odds ratio.
aSignificant variables (a¼ 0.10) in univariate analysis were included: treatment, ER, PR, Ki67,
PTEN. We used the stepwise method in SAS to identify variables associated to the
dependent variable.
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However, activation of the PI3K signalling pathway in the tumour
measured by PTEN expression and the phosphorylated (that is,
activated) form of AKT were not associated with response in our
patients. Similar results have been reported recently by the North
Central Cancer Treatment Group Trial N9831 in which the benefit
of adjuvant trastuzumab for patients with HER2-positive breast
cancer was independent of tumour PTEN status (Perez et al, 2013).
It has been described that HER2 signalling inhibition in breast
cancer by specific therapies resulted in a compensatory activation
of the ERK pathway mediated by activation of the HER family
receptors, inducing receptor dimerisation and phosphorylation,
HER3 overexpression and binding of adaptor molecules to
receptors. In HER2-positive, ER-positive breast cancer, ERK
activation in vitro has been involved as a compensatory signalling
mechanism (Emde et al, 2011). However, the analysis of ERK
activation in breast tumours in this study did not show an
association with response to trastuzumab or lapatinib therapy.
The main limitation of our study is that we report findings from
a randomised phase II trial when results from phase III trials using
the same therapy are already published. In fact, our findings
support those of the GeparQuinto study (Untch et al, 2012), a
phase III trial, showing that combining anthracyclines and taxanes
sequentially plus trastuzumab is more effective than the same
therapy plus lapatinib. However, the relevance of our results is
derived from the key difference between the two studies—that is,
the timing of the anti-HER2 therapy (trastuzumab or lapatinib). In
the GeparQuinto trial, patients receive trastuzumab concurrently
with anthracyclines, whereas in our study the anti-HER2 therapy is
only given with docetaxel. This difference is important for two
reasons. First, since questions regarding the long-term cardiac
toxicity associated with the combination of anthracyclines and
trastuzumab still remain, our design avoids this potential cause of
toxicity. Second, sequential drug delivery, as designed in our study,
does not appear to compromise treatment effectiveness, given the
similar pCRs found in both studies (and consistently greater for
chemotherapyþ trastuzumab than for chemotherapyþ lapatinib).
Our data have been confirmed by recently published results from
the study Z1041, which show that the concurrent use of
trastuzumab with anthracyclines, vs sequential use, does not
increase pCR rates (Buzdar et al, 2013). It is also worth noting that,
although there are no direct comparisons, pCR rates from
anthracyclines and taxanesþ trastuzumab (30–65%; Alba et al,
2011; Untch et al, 2012; Buzdar et al, 2013) are equal or greater
than the pCR from taxanes plus double-modulation with lapatinib
or pertuzumab (25–51%) (Baselga et al, 2012; Gianni et al, 2012;
Guarnieri et al, 2012). These data may generate hypotheses
regarding the potential for anthracyclines plus double modulation
to further increase pCR rates in this population. Thus, the main
contribution of our study to the existing literature and clinical
practice is that it confirms that trastuzumab is more effective than
lapatinib, and with lower acute toxicity, when delivered with
chemotherapy in the neoadjuvant treatment of patients with
tumours HER2þ . Our results further confirm that it is possible to
attain a pCR similar to double modulation or to protocols using
anthracyclines concurrently with trastuzumab, while reducing
potential late cardiotoxicity.
In conclusion, in the neoadjuvant treatment of HER2-positive
breast cancer patients, anthracycline- and taxane-based standard
chemotherapy with concurrent (only with taxane) trastuzumab has
shown to be more efficacious and less toxic than the standard
chemotherapy with lapatinib. Furthermore, our study confirms
that ER expression has a predictive role in the efficacy of standard
NAC combined with a HER2-targeted agent. It is essential for
future research to focus on the following: (a) the biology and
implications of the relationship between biomarkers and HER2-
related signalling pathways; and (b) the role of said relationships in
the efficacy of the anti-HER2 therapy.
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